NOVEMBER 2013

Health Canada approves Opsumit (macitentan) for sale in Canada for the treatment of PAH

MARCH 2014

Health Canada approves Adempas (riociguat) for sale in Canada for the treatment of PAH

OCTOBER 2014

Quebec begins providing public reimbursement for Opsumit

JANUARY 2015

Common Drug Review recommends Opsumit be publicly funded (with criteria and a condition) for the long-term treatment of PAH to reduce morbidity in patients with Functional Class II or III

FEBRUARY 2015

Quebec declines to list Adempas (riociguat) for public funding

MARCH 2015

The CADTH Therapeutic Review Recommendation Report of Drugs for PAH recommends a suboptimal stepped approach to initial PAH therapy

JUNE 2015

PHA Canada launches an advocacy campaign to ensure all PAH patients have publicly funded access to new and existing treatments at diagnosis and beyond; PHA Canada Ambassadors begin meeting with their local provincial government representatives

SEPTEMBER 2015

Scleroderma Society of Canada (SSC) launches an advocacy campaign during National Scleroderma Conference and distributes advocacy postcards to scleroderma patients and supporters across Canada addressed to the provincial Ministers of Health

NOVEMBER 2015

SSC and Scleroderma Association of Saskatchewan meet with the Saskatchewan Health Minister to discuss the importance of access to Opsumit for PAH patients

DECEMBER 3 2015

PHA Canada and SSC host an advocacy day at Queen's Park for Ontarians affected by PAH

DECEMBER 2015

Common Drug Review recommends Adempas be publicly funded (with criteria and a condition) for the treatment of PAH as monotherapy or in combination with ERAs in adult patients with Functional Class II or III

DECEMBER 2015

Provincial and territorial negotiations for Opsumit through the pan-Canadian Pharmaceutical Alliance (pCPA) are closed without coming to an agreement

JANUARY 2016

Health Canada approves Uptravi (selexipag) for sale in Canada for the treatment of PAH

FEBRUARY 2016

PHA Canada and SSC call on pCPA to re-open negotiations for Opsumit without further delay to ensure that all patients living with PAH have publically funded access to optimal treatment for their life-threatening disease

JUNE 2016

MPP Michael Harris delivers 833 postcards from PAH supporters in Ontario to Honourable Dr. Eric Hoskins, Minister of Health and Long-Term Care

JUNE 2016

SSC and Scleroderma Association of Saskatchewan have second meeting with the Saskatchewan Health Minister and deliver 106 postcards from PAH supporters in the province

JULY 2016

PHA Canada submits recommendations for improving funding criteria for PAH treatments to Ontario's Ministry of Health and Long-Term Care